

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Raphael GORODETSKY et al.

Confirmation No.: 3576

Application No.: 09/487,790

Patent No.: 7,122,620 B1

Filing Date: January 20, 2000

Patent Date: October 17, 2006

For: HAPTOTACTIC PEPTIDES

Attorney Docket No.: 85189-5700

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. § 1.322

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Patentees hereby respectfully request the issuance of a Certificate of Correction in connection with the above-identified patent. The correction is listed on the attached Form PTO-1050. The correction requested is as follows:

Title Page:

Item (73) Assignee, before "**Medical Research Services and Development Ltd.**" insert -- **Hadasit** --. The name of the assignee will then correctly appear as "**Hadasit Medical Research Services and Development Ltd.**" This change is requested to correct an inadvertent clerical error in completing the Issue Fee Transmittal Form PTOL-85.

A fee of \$100 is believed to be due for this request. Please charge the required fees to Winston & Strawn LLP Deposit Account No. 50-1814. Please issue a Certificate of Correction in due course.

Respectfully submitted,

4-4-07

Date



Allan A. Fanucci, Reg. No. 30,256

WINSTON & STRAWN LLP
Customer No. 28765

212-294-3311

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO.: 7,122,620 B1
APPLICATION NO.: 09/487,790
DATED: Oct. 17, 2006
INVENTOR(S): Gorodetsky et al.

Page 1 of 1

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title Page:

Item (73) Assignee, before "**Medical Research Services and Development Ltd.**" insert -- **Hadasit** --.



US007122620B1

(12) **United States Patent**
Gorodetsky et al.

(10) **Patent No.:** **US 7,122,620 B1**
 (45) **Date of Patent:** **Oct. 17, 2006**

(54) **HAPTOTACTIC PEPTIDES**

(75) Inventors: **Raphael Gorodetsky, Jerusalem (IL);**
Gerard Marx, N.Y., NY (US)

Hadasi

(73) Assignee: **Medical Research Services and**
Development Ltd., Jerusalem (IL)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/487,790**

(22) Filed: **Jan. 20, 2000**

Related U.S. Application Data

(63) Continuation-in-part of application No. 09/084,371, filed on May 27, 1998, now abandoned.

(51) **Int. Cl.**
A61K 38/00 (2006.01)
G01N 33/53 (2006.01)

(52) **U.S. Cl.** **530/300; 514/2; 424/278.1;**
435/7.1

(58) **Field of Classification Search** **530/300;**
530/350; 514/2; 424/278.1; 435/7.1
 See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,455,290 A	6/1984	Olexa et al.	424/1.1
5,292,362 A	3/1994	Bass et al.	106/124
5,428,014 A	6/1995	Labroo et al.	514/12
5,473,051 A	12/1995	Altieri et al.	530/382
5,599,790 A	2/1997	Altieri et al.	514/8
5,639,940 A	6/1997	Garner et al.	800/2
5,939,385 A	8/1999	Labroo et al.	514/12
6,083,902 A	7/2000	Cederholm-Williams	514/2
2004/0126758 A1	7/2004	Marx et al.	435/6

FOREIGN PATENT DOCUMENTS

WO WO 95/23868 * 9/1995
 WO WO 96/1041 A1 * 12/1999

OTHER PUBLICATIONS

Watt, K. W. K. et al. (1979) Amino acid sequence of the beta chain of human fibrinogen. *Biochemistry*, vol. 18, pp. 68-76.*
 Koopman, J. et al. (1992) Abnormal fibrinogens IIImiden (B beta Arg14—Cys) and Nijmegen (B beta Arg44—Cys) form disulfide-linked fibrinogen-albumin complexes. *Proc. Natl. Acad. Sci. U.S.A.* vol. 89, pp. 3478-3482.*
 Attachment 1: sequence alignment, pp. 1-3.*
 Pandya et al. (1985) Conservation of human fibrinogen conformation after cleavage of the B beta chain NH2 terminus. *J. Biol. Chem.* vol. 260, pp. 2994-3000.*
 Blumenstein et al. (1992) A beta-turn is present in the 392-411 segment of the human fibrinogen gamma-chain. Effects of structural changes in this segment on affinity to antibody 4A5. *Biochemistry*, vol. 31, pp. 10692-10698.*

Henschen et al. (1983) Covalent structure of fibrinogen. *Ann. N.Y. Acad. Sci.* vol. 408, pp. 28-43.*

Duga et al. (2000) Missense mutations in the human beta fibrinogen gene cause congenital afibrinogenemia by impairing fibrinogen secretion. *Blood*, vol. 95, pp. 1336-1341.*

Yee et al. (1997) Crystal structure of a 30 kDa C-terminal fragment from the gamma chain of human fibrinogen. *Structure*, vol. 5, pp. 125-138.*

Henschen et al. (1980) human fibrinogen sequence, sulfur bridge, glycosylation and some structural variants, in "Protides of the biological fluids" Proc. 28th Colloq., Peeters, H., ed., pp. 51-56.*
 Mayo et al. (1990) 1H NMR sequential assignments and secondary structure analysis of human fibrinogen gamma-chain C-terminal residues 385-411. *Biochemistry*, vol. 29, pp. 3277-3286.*

David R. Phillips et al., XP-002218130 "The Platelet Membrane Glycoprotein IIb-IIIa Complex", *The Journal of The American Society of Hematology*, Blood, vol. 71, No. 4, pp. 831-843 (1988).
 C.J. Nieman et al., XP-001118065, "A Colourimetric Enzyme-Linked Sandwich Assay For The Detection Of Human Platelets Bound To A Fibrinogen-Coated Surface", *Thrombosis Research*, vol. 62, pp. 189-197 (1991).

Yiping Fu et al., XP-002218053 "Fibrinogen α Genes: Conservation of Bipartite Transcripts and Carboxy-Terminal-Extended α Subunits in Vertebrates", *GENOMICS*, vol. 30, pp. 71-76 (1995).
 W. D. Thompson et al., XP-000983610, "Angiogenic Activity Of Fibrin Degradation Products Is Located In Fibrin Fragment E", *Department of Pathology and Clinical Biochemistry, Journal Of Pathology*, vol. 168, pp. 47-53 (1992).

Dominic W. Chung et al., "Characterization of Complementary Deoxyribonucleic Acid and Genomic Deoxyribonucleic Acid for the β Chain of Human Fibrinogen", *American Chemical Society, Biochemistry*, vol. 22, pp. 3244-3250 (1983).

Michael Blumenstein et al., "A β -Turn Is Present in the 392-411 Segment of the Human Fibrinogen γ -Chain. Effects of Structural Changes in This Segment on Affinity to Antibody 4A5", *American Chemical Society, Biochemistry*, vol. 31, pp. 10692-10698 (1992).

Yiping Fu et al., "Carboxy-Terminal-Extended Variant of the Human Fibrinogen α Subunit: A Novel Exon Confering Marked Homology to β and γ Subunits", *American Chemical Society, Biochemistry*, vol. 31, pp. 11958-11972 (1992).

Cezary Watala et al., "Microenvironmental changes in platelet membranes induced by the interaction of fibrinogen-derived peptide ligands with platelet integrins", *Eur. J. Biochem.*, vol. 235, pp. 281-288 (1996).

* cited by examiner

Primary Examiner—Jon Weber
Assistant Examiner—Samuel Wei Liao
 (74) *Attorney, Agent, or Firm*—Winston & Strawn LLP

(57)

ABSTRACT

This invention is related to a novel peptide consisting of the amino acid sequence of SEQ ID NO:1, and a pharmaceutical composition comprising the peptide thereof.

4 Claims, 7 Drawing Sheets